Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Baxter

Last Updated: February 1, 2023

Details for Patent: RE46375


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: RE46375
Title:6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Abstract: A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I): ##STR00001## wherein R.sup.1 and R.sup.2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., R.sup.3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., R.sup.4 is hydrogen or lower alkyl, R.sup.5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl, or a pharmaceutically .[.acceptably.]. .Iadd.acceptable .Iaddend.salt, or a solvate thereof is provided.
Inventor(s): Inagaki; Masanao (Toyonaka, JP), Hara; Shin-ichiro (Toyonaka, JP), Haga; Nobuhiro (Osaka, JP), Tamura; Yoshinori (Toyonaka, JP), Goto; Yoshihisa (Amagasaki, JP), Hasegawa; Tsuyoshi (Toyonaka, JP)
Assignee: Shionogi & Co., Ltd. (Osaka, JP)
Application Number:15/064,538
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Delivery; Dosage form;

Drugs Protected by US Patent RE46375

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bdsi SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF OPIOID-INDUCED CONSTIPATION See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE46375

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/JP2006/310231May 23, 2006

International Family Members for US Patent RE46375

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006250390 See Plans and Pricing
Brazil PI0610343 See Plans and Pricing
Canada 2609733 See Plans and Pricing
China 101228172 See Plans and Pricing
Denmark 1889848 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Express Scripts
McKesson
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.